CONTENTS

4 OVERVIEW

4 Drug Overview

5 Product Profiles

5 Velcade : Multiple myeloma

23 Velcade : NHL: Mantle cell lymphoma (MCL)

LIST OF FIGURES
12 Figure 1: Velcade for multiple myeloma - SWOT analysis

13 Figure 2: Datamonitor Healthcare's drug assessment summary of Velcade for multiple myeloma

14 Figure 3: Datamonitor Healthcare's drug assessment summary of Velcade for multiple myeloma

17 Figure 4: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017-26

26 Figure 5: Velcade for mantle cell lymphoma - SWOT analysis

27 Figure 6: Datamonitor Healthcare's drug assessment summary of Velcade in mantle cell lymphoma

28 Figure 7: Datamonitor Healthcare's drug assessment summary of Velcade in mantle cell lymphoma

LIST OF TABLES
5 Table 1: Velcade drug profile

7 Table 2: Velcade pivotal trial data in multiple myeloma

10 Table 3: Velcade late-phase trial data in multiple myeloma

18 Table 4: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017-26

20 Table 5: Patients treated with Velcade in the US, Japan, and five major EU markets, by country, 2017-26

24 Table 6: Velcade drug profile
25 Table 7: Velcade pivotal trial data in mantle cell lymphoma